Lantern Pharma Inc Dossier
Qualitative Analysis
Business overview
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company pioneering the integration of artificial intelligence, machine learning, and genomic data to streamline and accelerate oncology drug discovery and development. The company leverages its proprietary Response Algorithm for Drug Rescue in Oncology (RADRu0000) platform, which utilizes advanced machine learning algorithms and a vast database of oncology-focused data points to identify patient populations most likely to respond to its drug candidates. Lantern's pipeline features three clinical-stage small molecule candidates: LP-300 (in Phase 2 HARMONICu0012 trial for never-smokers with non-small cell lung cancer), LP-184 (in Phase 1a/1b trials for advanced solid tumors and glioblastoma), and LP-284 (targeting non-Hodgkin's lymphomas). Additionally, the company is advancing an antibody-drug conjugate (ADC) program and pediatric central nervous system cancer therapies through its subsidiary, Starlight Therapeutics.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Establishment of an AI Center of Excellence in Bengaluru, India, focused on large-scale data engineering, development of ML-ready disease models, and integration with global biopharma partners.
Expected impact: Industrializes the RADR® platform and withZeta.ai system, improves scalability to support multiple drug programs, and expands global biopharma development and licensing opportunities.
Commercial rollout of the withZeta.ai multi-agentic co-scientist platform via a subscription and usage-based model, followed by a strategic plan to separate the platform and related personnel into an independent business entity.
Expected impact: Unlocks distinct valuation multiples for the AI platform business separate from clinical-stage drug development, while establishing a recurring non-dilutive revenue stream.
Repositioning and expanding the predictBBB.ai platform from a blood-brain barrier permeability prediction tool into a molecular intelligence web service powered by a Large Quantitative Model (LQM).
Expected impact: Extends capabilities to a broader set of molecular and structural analyses to accelerate small molecule drug design and optimization for both CNS and non-CNS indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Aims to responsibly incorporate under-represented patient populations and real-world clinical data into RADR® and future AI modules, improving model generalizability and reflecting global genetic diversity.
Terms: Not specified.